Clinical trial · no report yet · Phase 2
PREcoopERA
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
- NCT05896566 ↗
- Completed
- ETOP IBCSG Partners Foundation
- 22 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 11 | |
| YouTube | 6 | |
| Podcasts | 3 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Breast Cancer
- Interventions
- Giredestrant; Triptorelin; Anastrozole
- Arms
- Arm A: Giredestrant · Experimental
- Arm B: Giredestrant plus triptorelin · Experimental
- Arm C: Anastrozole plus triptorelin · Active comparator
- Enrollment
- 231
- Primary outcomes
- Change in Ki 67
- Sponsor
- ETOP IBCSG Partners Foundation with Hoffmann-La Roche
- Start
- Jan 23, 2024
- Primary completion
- Sep 18, 2025
- Results posted
- No
- Registry record
- NCT05896566 · updated Feb 24, 2026